MCID: GLM007
MIFTS: 60

Glomerulonephritis

Categories: Blood diseases, Immune diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Glomerulonephritis

MalaCards integrated aliases for Glomerulonephritis:

Name: Glomerulonephritis 12 74 20 54 6 44 15 37 71
Bright's Disease 20

Classifications:



External Ids:

Disease Ontology 12 DOID:2921
MeSH 44 D005921
NCIt 50 C26784
SNOMED-CT 67 36171008
ICD10 32 N08
UMLS 71 C0017658

Summaries for Glomerulonephritis

GARD : 20 Glomerulonephritis is a type of kidney disease in which there is inflammation of the glomeruli, the tiny filters that remove excess waste and fluids from the blood. It may be acute or chronic (coming on gradually), and may occur on its own (primary) or be caused by another condition (secondary). Signs and symptoms may depend on the type and cause of the condition and may include blood in the urine; foamy urine; swelling of the face, eyes, or other body parts; abdominal pain; high blood pressure; fatigue; and/or other symptoms. If the condition is severe or prolonged, the kidneys can become damaged. It may be caused by a variety of infections and diseases, and sometimes the cause is unknown. Treatment depends on the cause, type and severity of the condition.

MalaCards based summary : Glomerulonephritis, also known as bright's disease, is related to c3 glomerulopathy and membranoproliferative glomerulonephritis. An important gene associated with Glomerulonephritis is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are Innate Immune System and Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include Kidney, neutrophil and endothelial, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Disease Ontology : 12 A nephritis that causes inflammation of the glomeruli located in kidney.

Wikipedia : 74 Glomerulonephritis (GN) is a term used to refer to several kidney diseases (usually affecting both... more...

Related Diseases for Glomerulonephritis

Diseases in the Glomerulonephritis family:

Autoimmune Glomerulonephritis Subacute Glomerulonephritis

Diseases related to Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1174)
# Related Disease Score Top Affiliating Genes
1 c3 glomerulopathy 33.1 CFI CFHR5 CFH C3
2 membranoproliferative glomerulonephritis 33.0 NPHS1 CFHR5 CFH CD79A C4A C3
3 dense deposit disease 33.0 CFHR5 CFH C3
4 crescentic glomerulonephritis 32.8 PRTN3 MPO CCL2
5 membranous nephropathy 32.8 NPHS1 MPO LRP2 CD79A C3 ALB
6 rapidly progressive glomerulonephritis 32.8 PRTN3 NPHS1 MPO COL4A4 COL4A3 C3
7 acute proliferative glomerulonephritis 32.8 PRTN3 NPHS1 MPO COL4A3 CCL2 C3
8 proliferative glomerulonephritis 32.8 MPO CR1 CFH CCL2 C3
9 iga glomerulonephritis 32.7 PRTN3 NPHS1 CFH CD79A CCL2 C4A
10 complement factor h deficiency 32.7 CFI CFH
11 acute poststreptococcal glomerulonephritis 32.7 CFHR5 CFH CD79A C3 ALB
12 immune-complex glomerulonephritis 32.6 MPO CFI C4B C3 ALB
13 exudative glomerulonephritis 32.5 CFHR5 CFH
14 goodpasture syndrome 32.5 PRTN3 NPHS1 MPO COL4A5 COL4A4 COL4A3
15 anti-basement membrane glomerulonephritis 32.2 PRTN3 MPO COL4A5 COL4A4 COL4A3 ALB
16 lipoid nephrosis 32.2 NPHS1 CD79A CCL2 APOL1 ALB
17 henoch-schoenlein purpura 32.1 PRTN3 MPO CD79A C3 ALB
18 vasculitis 32.0 PRTN3 MPO CD79A CCL2 C3
19 glomerular disease 31.9 CD79A ALB
20 acute kidney failure 31.9 PRTN3 CFH ALB
21 alport syndrome 3, autosomal dominant 31.9 COL4A4 COL4A3
22 complement factor i deficiency 31.8 CR1 CFI C4B C4A C3
23 alport syndrome 1, x-linked 31.8 COL4A5 COL4A4
24 anca-associated vasculitis 31.7 PRTN3 MPO C3
25 lupus erythematosus 31.6 CR1 C4B C4A C3 C1QC
26 autoimmune disease 31.5 PRTN3 MPO CD79A CCL2 C3
27 proteinuria, chronic benign 31.5 NPHS1 LRP2 COL4A5 COL4A4 COL4A3 CD79A
28 alport syndrome 31.3 NPHS1 MYH9 COL4A5 COL4A4 COL4A3 CFHR5
29 systemic lupus erythematosus 31.3 PRTN3 MPO CR1 CFI CD79A CCL2
30 nephrosclerosis 31.2 NPHS1 MPO CCL2
31 hemolytic-uremic syndrome 31.2 CFI CFHR5 CFH C4B C3
32 hemolytic anemia 31.1 CR1 CFI CFH C3
33 syphilis 31.1 PRTN3 CD79A ALB
34 pulmonary hemosiderosis 31.1 PRTN3 MPO
35 proteasome-associated autoinflammatory syndrome 1 31.0 MPO CCL2 ALB
36 acute kidney tubular necrosis 31.0 LRP2 CCL2 ALB
37 focal segmental glomerulosclerosis 30.9 NPHS1 MYH9 COL4A5 COL4A4 COL4A3 CCL2
38 subacute bacterial endocarditis 30.9 PRTN3 MPO
39 arteriolosclerosis 30.8 CD79A C3 ALB
40 end stage renal disease 30.8 NPHS1 MYH9 COL4A5 COL4A4 COL4A3 CFHR5
41 thrombotic thrombocytopenic purpura 30.8 CFI CFH C3
42 antiphospholipid syndrome 30.8 CFH CD79A C3
43 thrombocytopenia 30.8 MYH9 CFI CFHR5 CFH CD79A CCL2
44 kidney disease 30.8 PRTN3 NPHS1 MYH9 LRP2 COL4A5 COL4A4
45 chronic kidney disease 30.7 NPHS1 MYH9 MPO COL4A5 COL4A4 COL4A3
46 cholangitis 30.7 PRTN3 MPO ALB
47 complement deficiency 30.7 CFI CFHR5 CFH C4B C4A C3
48 hemolytic uremic syndrome, atypical 1 30.7 CR1 CFI CFHR5 CFH C4B C4A
49 pyuria 30.7 PRTN3 C3 ALB
50 hemoglobinuria 30.7 CR1 CFI C3

Graphical network of the top 20 diseases related to Glomerulonephritis:



Diseases related to Glomerulonephritis

Symptoms & Phenotypes for Glomerulonephritis

GenomeRNAi Phenotypes related to Glomerulonephritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 ALB C1QC C3 C4A CCL2 CD79A

MGI Mouse Phenotypes related to Glomerulonephritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 C3 C4B CD79A CFH CFI COL4A3
2 homeostasis/metabolism MP:0005376 10 ALB C1QC C3 C4B CD79A CFH
3 immune system MP:0005387 9.8 ALB C3 C4B CCL2 CD79A CFH
4 renal/urinary system MP:0005367 9.4 ALB C3 C4B CD79A CFH CFI

Drugs & Therapeutics for Glomerulonephritis

Drugs for Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Probucol Approved, Investigational Phase 4 23288-49-5 4912
5
Enalaprilat Approved Phase 4 76420-72-9 6917719
6
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
7
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
8
Hydroxychloroquine Approved Phase 4 118-42-3 3652
9
rituximab Approved Phase 4 174722-31-7 10201696
10
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Azathioprine Approved Phase 4 446-86-6 2265
13
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
14
Mycophenolic acid Approved Phase 4 24280-93-1 446541
15
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
16
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
17
Ramipril Approved Phase 4 87333-19-5 5362129
18
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
19
Canagliflozin Approved Phase 4 842133-18-0
20
Empagliflozin Approved Phase 4 864070-44-0
21
Losartan Approved Phase 4 114798-26-4 3961
22
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
23 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
24
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
25
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
26
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
27
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
28
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
29
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
30
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
31
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
32
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
33
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
34 HIV Protease Inhibitors Phase 4
35
protease inhibitors Phase 4
36 Mitogens Phase 4
37 Interferon-alpha Phase 4
38 interferons Phase 4
39 Cassava Phase 4
40 Calcium, Dietary Phase 4
41 Micronutrients Phase 4
42 Nutrients Phase 4
43 Trace Elements Phase 4
44 Vitamins Phase 4
45 Vasoconstrictor Agents Phase 4
46 Antimetabolites Phase 4
47 Omega 3 Fatty Acid Phase 4
48 Anticholesteremic Agents Phase 4
49 Proteasome Inhibitors Phase 4
50 Antimalarials Phase 4

Interventional clinical trials:

(show top 50) (show all 245)
# Name Status NCT ID Phase Drugs
1 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
2 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
3 The Therapy of Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis : A Multicenter, Prospective, Randomized, Controlled, Single-blind Trial. Unknown status NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
4 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
5 A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
6 A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Unknown status NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
7 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
8 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
9 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
10 A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Unknown status NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
11 The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy Completed NCT00319761 Phase 4 Calcitriol
12 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
13 Low-dose Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: a 12-month Prospective Study Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
14 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
15 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
16 Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
17 A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
18 Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Completed NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
19 Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
20 Velcade Therapy for Severe IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
21 Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
22 A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
23 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
24 To Compare the Efficacy and Safety of TW vs Valsartan in the MN Completed NCT00518219 Phase 4 TW
25 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
26 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
27 Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study Completed NCT00922311 Phase 4 Aliskiren
28 Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy Recruiting NCT03025828 Phase 4 ACTHar
29 A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency Recruiting NCT04020328 Phase 4 Leflunomide 20 mg+prednisone 0.5mg/kg/d
30 Immunoadsorption in Anti-glomerular Basement Membrane Glomerulonephritis; a Pilot Study Recruiting NCT02765789 Phase 4
31 A Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA Nephropathy Recruiting NCT04525729 Phase 4 Rituximab;RAS 2410
32 An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
33 Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Not yet recruiting NCT04662723 Phase 4 Corticosteroid;Renin-angiotensin sytem blockers;Sodium-glucose cotransporter 2 inhibitor
34 Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis: A Multicentre Prospective, Randomized, Double-blind and Imitation, Positive-drug Parallel Controlled Clinical Trail Not yet recruiting NCT04263922 Phase 4 Huaiqihuang granules;Valsartan capsule
35 Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis:A Multicenter Randomized Controlled Clinical Trial Not yet recruiting NCT04349683 Phase 4 Jinshuibao;Placebo
36 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
37 Multitarget Therapy for Idiopathic Membranous Nephropathy Not yet recruiting NCT04424862 Phase 4 Prednisone, ciclosporin and mycophenolate mofetil;Ponticelli Regimen
38 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
39 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Terminated NCT02523768 Phase 4 ATG-F;Simulect
40 An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Withdrawn NCT01926054 Phase 4 Acthar gel
41 Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
42 ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study Unknown status NCT02155803 Phase 2, Phase 3 ACTHAR Gel (adrenocorticotropic hormone)
43 A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid
44 Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis Unknown status NCT03180723 Phase 3 Rituximab;Cyclosporin
45 Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f Unknown status NCT02187900 Phase 3 Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF)
46 Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy -- A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02662283 Phase 2, Phase 3 Prednisolone;Reh-acteoside
47 Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN) Unknown status NCT01508468 Phase 3 symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
48 The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Completed NCT00870493 Phase 3 Aliskiren;Placebo
49 Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy Completed NCT00135954 Phase 3 Cyclophosphamide and steroids
50 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil

Search NIH Clinical Center for Glomerulonephritis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Glomerulonephritis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Glomerulonephritis:
Mesenchymal stromal cells for glomerulonephritis
Embryonic/Adult Cultured Cells Related to Glomerulonephritis:
Bone marrow-derived mesenchymal stromal cells PMIDs: 22172807

Cochrane evidence based reviews: glomerulonephritis

Genetic Tests for Glomerulonephritis

Anatomical Context for Glomerulonephritis

The Foundational Model of Anatomy Ontology organs/tissues related to Glomerulonephritis:

19
Kidney

MalaCards organs/tissues related to Glomerulonephritis:

40
Kidney, Neutrophil, Endothelial, T Cells, Skin, Bone Marrow, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Glomerulonephritis:
# Tissue Anatomical CompartmentCell Relevance
1 Kidney Glomerulus Affected by disease

Publications for Glomerulonephritis

Articles related to Glomerulonephritis:

(show top 50) (show all 28023)
# Title Authors PMID Year
1
Suppression of nephrin expression by TNF-alpha via interfering with the cAMP-retinoic acid receptor pathway. 54 61
20237236 2010
2
T cells, adhesion molecules and modulation of apoptosis in visceral leishmaniasis glomerulonephritis. 54 61
20459816 2010
3
Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation. 54 61
20155828 2010
4
Autoimmune kidney diseases. 54 61
19906361 2010
5
Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. 61 54
20042261 2010
6
Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis. 61 54
19898926 2010
7
Ameliorative effects of arctiin from Arctium lappa on experimental glomerulonephritis in rats. 54 61
19524415 2009
8
Parallel genotyping of 10,204 single nucleotide polymorphisms to screen for susceptible genes for IgA nephropathy. 54 61
19890582 2009
9
[Expression of MCP-1 in renal tissues of patients with IgA nephropathy]. 61 54
19893256 2009
10
Hepatitis B virus associated focal and segmental glomerular sclerosis: report of two cases and review of literature. 54 61
19169768 2009
11
Resolution of IgM nephropathy after rituximab treatment. 54 61
19084309 2009
12
Analyzing antibody activity in IgA nephropathy. 61 54
19504718 2009
13
Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. 54 61
19067130 2009
14
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. 54 61
19264905 2009
15
Molecular heterogeneity of urinary albumin in glomerulonephritis: comparison of cardiovascular disease with albuminuria. 54 61
19150611 2009
16
Vasculitic IgA nephropathy: prognosis and outcome. 61 54
19342865 2009
17
Glomerular diseases in a Hispanic population: review of a regional renal biopsy database. 54 61
19820874 2009
18
Transforming growth factor-beta 1 in Balkan endemic nephropathy. 54 61
19147994 2009
19
Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis. 54 61
19587833 2009
20
[MPO-positive cells and extracellular MPO in the glomeruli of MPO-ANCA-associated glomerulonephritis]. 54 61
19238910 2009
21
A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe. 61 54
19210866 2008
22
The protective role of uteroglobin through the modulation of tissue transglutaminase in the experimental crescentic glomerulonephritis. 54 61
18558621 2008
23
Antigenic heterogeneity of IgA anti-GBM disease: new renal targets of IgA autoantibodies. 61 54
18752876 2008
24
Valvular injury in a patient with PR3-ANCA-associated glomerulonephritis. 61 54
18762796 2008
25
Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. 61 54
18725016 2008
26
[Crohn's disease in association with IgA nephropathy]. 61 54
19077504 2008
27
IgA nephropathy: lessons from an animal model, the ddY mouse. 54 61
18651534 2008
28
Deletion of IL-18 receptor ameliorates renal injury in bovine serum albumin-induced glomerulonephritis. 54 61
18462998 2008
29
Increased plasma acylation-stimulating protein in pediatric proteinuric renal disease. 54 61
18253759 2008
30
Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. 54 61
18538590 2008
31
Smad7 as a therapeutic agent for chronic kidney diseases. 54 61
18508563 2008
32
Scleroderma with crescentic glomerulonephritis: a case report. 61 54
18474117 2008
33
Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. 54 61
18371543 2008
34
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis. 61 54
18497456 2008
35
Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. 61 54
17914026 2008
36
Role of macrophage migration inhibition factor in kidney disease. 54 61
18663334 2008
37
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. 61 54
18925530 2008
38
Should a renal biopsy be performed at the first relapse of 'clinical nephrotic syndrome'? 54 61
18365928 2008
39
Remission of proteinuria improves prognosis in IgA nephropathy. 54 61
17978307 2007
40
Intramolecular epitope spreading in Heymann nephritis. 61 54
18003776 2007
41
The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. 61 54
18055544 2007
42
Chemically modified siRNA prolonged RNA interference in renal disease. 54 61
17880921 2007
43
Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome). 54 61
17655694 2007
44
Streptococcal exotoxin B increases interleukin-6, tumor necrosis factor alpha, interleukin-8 and transforming growth factor beta-1 in leukocytes. 54 61
17530297 2007
45
Lack of association between NPHS2 gene polymorphisms and sporadic IgA nephropathy. 61 54
17635752 2007
46
Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. 61 54
17342176 2007
47
Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis. 61 54
17205957 2007
48
PDGF-B gene single-nucleotide polymorphisms are not predictive for disease onset or progression of IgA nephropathy. 61 54
17338425 2007
49
Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. 61 54
17040997 2007
50
Association between the clara cell secretory protein (CC16) G38A polymorphism and the progression of IgA nephropathy. 61 54
17338426 2007

Variations for Glomerulonephritis

ClinVar genetic disease variations for Glomerulonephritis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APOL1 NM_003661.4(APOL1):c.1024A>G (p.Ser342Gly) SNV Pathogenic 277678 rs73885319 22:36661906-36661906 22:36265860-36265860
2 APOL1 NM_003661.4(APOL1):c.1152T>G (p.Ile384Met) SNV Pathogenic 127198 rs60910145 22:36662034-36662034 22:36265988-36265988
3 COL4A4 NM_000092.5(COL4A4):c.854G>A (p.Gly285Glu) SNV Likely pathogenic 930185 2:227967876-227967876 2:227103160-227103160
4 COL4A4 NM_000092.5(COL4A4):c.788C>G (p.Pro263Arg) SNV Uncertain significance 930186 2:227968716-227968716 2:227104000-227104000
5 COL4A4 NM_000092.5(COL4A4):c.1246C>G (p.Pro416Ala) SNV Uncertain significance 930187 2:227958964-227958964 2:227094248-227094248
6 LAMB2 NM_002292.4(LAMB2):c.4307G>A (p.Arg1436His) SNV Uncertain significance 930193 3:49160403-49160403 3:49122970-49122970
7 MYH9 NM_002473.5(MYH9):c.5185G>T (p.Ala1729Ser) SNV Uncertain significance 499790 rs140662138 22:36681793-36681793 22:36285747-36285747
8 NPHS1 NM_004646.4(NPHS1):c.2344G>A (p.Glu782Lys) SNV Uncertain significance 930197 19:36333443-36333443 19:35842541-35842541
9 PLCE1 NM_016341.4(PLCE1):c.756G>T (p.Gln252His) SNV Uncertain significance 930200 10:95791559-95791559 10:94031802-94031802
10 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro) SNV Uncertain significance 128688 rs587780309 9:135946855-135946855 9:133071468-133071468

Copy number variations for Glomerulonephritis from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21052 1 156500000 165500000 Copy number FCGR3A Glomerulonephritis
2 21055 1 156500000 165500000 Loss FCGR3B Glomerulonephritis
3 21056 1 156500000 165500000 Low copy number FCGR3B Glomerulonephritis

Expression for Glomerulonephritis

Search GEO for disease gene expression data for Glomerulonephritis.

Pathways for Glomerulonephritis

Pathways related to Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 PRTN3 MYH9 MPO CR1 CFI CFH
2
Show member pathways
12.4 MYH9 COL4A5 COL4A4 COL4A3
3
Show member pathways
12.17 MPO LRP2 CCL2 ALB
4
Show member pathways
12 CR1 CFI CFH C4B C4A C3
5 11.78 CFI CFH C4B C4A C3 C1QC
6 11.75 COL4A5 COL4A4 COL4A3
7 11.73 COL4A5 COL4A4 COL4A3 CCL2
8 11.7 COL4A5 COL4A4 COL4A3
9
Show member pathways
11.66 CR1 CFI CFH C4B C4A C3
10
Show member pathways
11.61 C4B C4A C3 C1QC
11 11.55 C4B C4A C3 C1QC
12 11.5 NPHS1 MYH9 CR1 COL4A5 COL4A4 COL4A3
13 11.49 COL4A5 COL4A4 COL4A3
14 11.39 CR1 CFI CFHR5 CFH C4B C4A
15 11.38 COL4A5 COL4A4 COL4A3
16 11.26 COL4A5 COL4A4 COL4A3
17 11.2 COL4A5 COL4A4 COL4A3
18 10.78 MPO CCL2

GO Terms for Glomerulonephritis

Cellular components related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.1 PRTN3 NPHS1 MYH9 MPO LRP2 CR1
2 collagen-containing extracellular matrix GO:0062023 9.83 PRTN3 COL4A5 COL4A4 COL4A3 C1QC
3 extracellular region GO:0005576 9.83 PRTN3 MPO COL4A5 COL4A4 COL4A3 CFI
4 endoplasmic reticulum lumen GO:0005788 9.8 COL4A5 COL4A4 COL4A3 C4A C3 APOL1
5 collagen trimer GO:0005581 9.71 COL4A5 COL4A4 COL4A3 C1QC
6 blood microparticle GO:0072562 9.7 CFH C4B C4A C3 C1QC APOL1
7 basement membrane GO:0005604 9.65 COL4A5 COL4A4 COL4A3
8 azurophil granule lumen GO:0035578 9.63 PRTN3 MPO C3
9 collagen type IV trimer GO:0005587 9.54 COL4A5 COL4A4 COL4A3
10 extracellular space GO:0005615 9.47 PRTN3 MPO COL4A5 COL4A4 COL4A3 CFI

Biological processes related to Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.03 CR1 CFI CFH CD79A C4B C4A
2 innate immune response GO:0045087 9.92 CR1 CFI CFH C4B C4A C3
3 cellular protein metabolic process GO:0044267 9.8 C4A C3 APOL1 ALB
4 negative regulation of endopeptidase activity GO:0010951 9.78 COL4A3 C4B C4A C3
5 complement activation GO:0006956 9.77 CFH C4B C4A C3 C1QC
6 complement activation, classical pathway GO:0006958 9.73 CR1 CFI C4B C4A C3 C1QC
7 glomerular basement membrane development GO:0032836 9.58 NPHS1 COL4A4 COL4A3
8 amyloid-beta clearance GO:0097242 9.54 LRP2 C3
9 collagen-activated tyrosine kinase receptor signaling pathway GO:0038063 9.52 COL4A5 COL4A3
10 cytolysis by host of symbiont cells GO:0051838 9.51 CFHR5 APOL1
11 positive regulation of activation of membrane attack complex GO:0001970 9.46 CR1 C3
12 complement activation, alternative pathway GO:0006957 9.46 CR1 CFHR5 CFH C3
13 positive regulation of apoptotic cell clearance GO:2000427 9.26 CCL2 C4B C4A C3
14 regulation of complement activation GO:0030449 9.23 CR1 CFI CFHR5 CFH C4B C4A

Molecular functions related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.13 PRTN3 NPHS1 MYH9 MPO LRP2 CR1
2 endopeptidase inhibitor activity GO:0004866 9.13 C4B C4A C3
3 extracellular matrix structural constituent conferring tensile strength GO:0030020 8.8 COL4A5 COL4A4 COL4A3

Sources for Glomerulonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....